Merck and Ridgeback Biotherapeutics Announce Initiation of Phase 3 Study (MOVe-NOW) Evaluating LAGEVRIO™ (molnupiravir) for the Treatment of COVID-19 in High-Risk Adults
Portfolio Pulse from
Merck and Ridgeback Biotherapeutics have announced the start of a Phase 3 study for LAGEVRIO (molnupiravir) aimed at treating COVID-19 in high-risk adults.
December 05, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Merck has initiated a Phase 3 study for its COVID-19 treatment, LAGEVRIO, in high-risk adults, which could impact its stock price positively if successful.
The initiation of a Phase 3 study for LAGEVRIO indicates progress in Merck's COVID-19 treatment efforts. Successful results could lead to regulatory approval and increased demand, positively impacting Merck's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90